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Summary We report on rates of patient retention and attrition in the context of scaling-
up antiretroviral treatment (ART) within a district hospital and its primary health centres in
rural Malawi. ‘Retention’ was deﬁned as being alive and on ART or transferred out, whereas
‘attrition’ was deﬁned as died, lost to follow-up or stopped treatment. A total of 4074 patients
were followed-up for 1803 person-years: 2904 were at the hospital and 1170 at health centres.
Approximately 85% of patients were retained in care, both at hospital and health centres, with
a retention rate per 100 person-years of 185 and 211, respectively [adjusted hazard ratio (HR)
1.18, 95% CI 1.10—1.28, P = 0.001). Attrition rates per 100 person-years were similar: 33 and
36, respectively (adjusted HR 1.17, 95% CI 0.97—1.4, P = 0.1). At health centres the incidence
of loss to follow-up was signiﬁcantly lower than at the hospital (adjusted HR 0.24, P < 0.001,
risk reduction 77%), but the rate of reported deaths was higher at health centres (adjusted HR
2.2, 95% CI 1.76—2.72, P < 0.001). As Malawi continues to extend the coverage (and equity) of
ART, including in rural areas, attention is needed to reduce losses to follow-up at hospital level
and reduce mortality at primary care level.
© 2009 Royal Society of Tropica
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. Introduction‘The hospital is too far away’’; ‘‘I missed my appoint-
ent because I could not ﬁnd enough money for
ransport’’. For anyone who works in rural districts in
frica, this sort of statement from a patient brings no
urprises. Many health-related interventions are often
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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centralised in hospitals that are located far from rural
communities.
Malawi is a small resource-limited country in southern
Africa with about 12million inhabitants and is facing a
severe HIV/AIDS epidemic, with an estimated 900 000 indi-
viduals living with HIV/AIDS and 60 000 AIDS-related deaths
each year.1 An estimated 275 000 people were thought to
be in need of antiretroviral therapy (ART) by the year 2007,
and by December 2007 141 449 patients had been placed
on treatment from 163 public health facilities (HIV Unit,
Ministry of Health, Malawi). Although this has been a com-
mendable achievement, these efforts have focused mainly
on second-level (hospital) facilities located principally in
urban areas. There is thus a valid concern of geographi-
cal equity in ART access for people living in rural areas,
where the cost of transport to hospitals is known to be
high and where ART uptake and follow-up may therefore be
compromised.2—4 Progressive congestion of existing hospital-
based ART clinics and the need for repeat visits, leading to
long waiting times, are also likely to add to the complexity
of accessing ART at the hospital level.
If geographical access is to be improved for the rural poor,
an unavoidable step is to decentralise ART to health centres.
In response to this challenge, from June 2006, Thyolo Dis-
trict in rural southern Malawi started to initiate ART both
at the district hospital and a number of primary health cen-
tres. Such a perspective of a hub (hospital) and spoke (health
centre) approach to ART roll-out is becoming common in sub-
Saharan Africa. However, concerns have been raised about
the human resource capacity and quality of ART delivery
that can be offered at health centres, and there is a dearth
of published data on ART outcomes that result from such
a decentralised approach to ART delivery in sub-Saharan
Africa.
From a public health perspective, patient retention and
attrition are important parameters that can be used to judge
program quality.5 We measured and compared these param-
eters among patients initiated on ART at the main district
hospital in Thyolo and its primary health centres.
2. Materials and methods
2.1. Study design, setting and population
This study was a retrospective cohort study and was con-
ducted in Thyolo, the largest rural district in Malawi, with
about 550 000 inhabitants. The inhabitants of Thyolo are
principally subsistence farmers, earning an average of US$4
per week. Of all income in the district, 80% comes from the
agricultural sector through daily labour in tea and coffee
plantations. The road networks are poor and public transport
is scarce and unaffordable to the majority.
The district has one main public hospital (Thyolo District
Hospital) and nine primary health centres. As from June
2006, health centres started initiating ART in a phased man-
ner, with seven of the nine starting during the study period.
All patients beginning ART for the ﬁrst time (ART naïve) at
the district hospital and health centres between 1 June 2006
and 31 June 2007 were included in this study.
All staff involved with ART delivery undergo a standard-
ized national training course, and ART delivery sites require
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ormal accreditation from the Ministry of Health before ART
ervices can commence. The district hospital ART clinics are
un by a team of one clinical ofﬁcer, two medical assistants,
wo nurses, three nurse counsellors and clerical support
taff. At the health centre level, ART delivery is managed
y a medical assistant, one nurse, a clerk and a reception-
st, who received appropriate training from either a doctor
r a senior clinician involved with ART delivery at the dis-
rict hospital. A mobile district team with a more senior
nd experienced clinician (a clinical ofﬁcer) provides ongo-
ng support and monitoring of hospital and health centres
n a monthly basis. A community network of home-based
are volunteers and community nurses facilitate care and
eferrals to existing health facilities, as has been described
reviously.6
General measures are provided in the Thyolo District ART
acilities to ensure patient conﬁdentiality, consent for HIV
esting, and counselling and support for those who receive a
ositive HIV test result. The data in this study did not include
atient identiﬁers.
.2. ART eligibility and regimens
ll HIV-positive patients assessed as being in WHO Clinical
tage 3 or 4, or with a CD4 count <250 cells/mm3 (irrespec-
ive of WHO staging) are considered eligible for ART.7 CD4
ounts were not routinely available at health centres dur-
ng the study period. Once patients are assessed as eligible
or ART, they are required to return with a patient guardian
or next of kin) to prepare for ART initiation. Patients and
uardians undergo group and individual counselling sessions
nd are educated on HIV infection, and the implications of
RT therapy. Once started on ART, patients are reviewed
ack at the HIV/AIDS clinic after 2 weeks. From then on,
rovided there are no side effects, patients are seen and
iven drugs at 4 week intervals.
The ﬁrst-line ART regimen in Malawi7 is a ﬁxed-dose com-
ination of stavudine (d4T), lamivudine (3TC) and nevirapine
NVP) (Triomune). In case of d4T- and NVP-related side
ffects, the respective alternatives are zidovudine (AZT)
nd efavirenz (EFV). ART is offered free of charge in all
ublic facilities in Malawi, including Thyolo.
.3. Data collection, treatment outcomes and
tatistical analysis
RT monitoring is done using standardized monitoring tools:
tandardized treatment outcomes are monitored every
onth in the patient master cards and updated each month
n the ART register, which have been described previously.8,9
reatment outcomes are deﬁned as: (1) alive and on ART
a patient who is alive and on ART at the facility where
e/she is registered; (2) died — a patient who has died for
ny reason while on ART; (3) lost to follow-up (defaulted) —
patient placed on ART that has not been seen at the ART
acility for a period of 3 months; (4) stopped — a patient who
s known to have stopped treatment for any reason during
reatment; (5) transferred out — a patient who is transferred
ut permanently to another treatment facility.
For the purposes of this analysis, ‘retention in care’
efers to patients who are alive and on ART at the same facil-
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ty or those formally transferred out to another ART unit and
hus assumed to be on therapy. ‘Attrition’ is deﬁned as dis-
ontinuation of ART for any reason, and includes death, loss
o follow-up and stopping ART medications.5 A district super-
isory team systematically checks the validity of outcome
ata on a monthly basis and reports to a national supervi-
ory team that cross-checks these data independently every
uarter. Data were collated for the hospital and the seven
ealth centres and treatment outcomes of all patients start-
ng ART from June 2006 were censored on 30 June 2007.
Differences between groups were compared using the 2
est for categorical variables and the Wilcoxon rank-sum
est. Hazard ratios (HR) per 100 person-years of follow-up
ere used to compare ART outcomes between hospital and
ealth centres. The rates of death and loss to follow-up in
he two groups were adjusted using a Cox regression model.
stimates were determined using the Kaplan—Maier method
nd compared using the Cox—Mantel (log-rank) test. The
evel of signiﬁcance was set at P = 0.05 or less and 95% CI
ere used throughout. Data analysis was done using STATA
.2 (Stata Corp., College Station, TX, USA).
. Results
.1. Characteristics of the study population and
reatment outcomes
here were 4098 patients who were started on ART during
he study period. Of these, 24 patients were excluded from
he analysis: 7 patients had initiated ART in another district
nd were transferred out; and date of treatment initiation
as not indicated in 17 patients. A total of 4074 patients
as included in the study: 2904 started ART at the district
ospital; and 1170 started ART at the health centres.
Table 1 shows the basic details of patients starting ART at
he two sites. At health centres, there was a higher propor-
0
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Table 1 Case registration characteristics of patients started on an
Thyolo District, Malawi
Variable Hospital n (%
Total 2904
Sex
Male 1123 (38.7)
Female 1781 (61.3)
Age (years)
Children <15 352 (12.1)
Adults ≥15 2552 (87.9)
Age (years) [median (IQR)] 31.8 (26—4
WHO clinical stage
Stage I or II with CD4 <250 cells/l 126 (4.3)
Stage III 2267 (78)
Stage IV 551 (18)
Active TB
No 2824 (97.3)
Yes 80 (2.7)
IQR: interquartile range.M. Massaquoi et al.
ion of women, patients at WHO stage 3 and patients with
ctive tuberculosis (TB) who started ART; whereas at the
ospital a higher proportion of patients started on ART as
result of being at WHO stages 1 and 2 with a low CD4
ount or at WHO Stage 4. Patients were followed-up for
total period of 1803 person-years. This included a total
ollow-up time of 1330 person-years in the hospital cohort
nd 473 person-years in the health centre cohort. Table 2
hows standardized treatment outcomes in person-years for
ll patients started on ART at hospital and health centres
nd censored on 30 June 2007.
.2. Retention in care
lthough retention rates at both hospital and health cen-
res were close to 85%, the rate at health centres was
igniﬁcantly higher (adjusted HR 1.18, 95% CI 1.10—1.28,
= 0.001). Individuals starting ART at health centres had a
2.3% (95% CI 5.7—18.5) higher attributable risk of being
etained in care than those at hospital (Table 2).
.3. Attrition from care
verall rates of attrition at hospital and health centres were
imilar (Table 2). After adjustment for sex, age, WHO stage
nd TB, the HR remained insigniﬁcant (HR 1.17, 95% CI
.97—1.4, P = 0.1).
Figure 1 shows the probability of attrition from care
mong patients starting ART at the hospital and health cen-
res. The rate of loss to follow-up at health centres was
igniﬁcantly lower than at the hospital (Table 2, adjusted HR
.24, 95% CI 0.14—0.39, P < 0.001). There was a 77% over-
ll absolute risk reduction in loss to follow-up (becoming
defaulter) in patients who started ART at health centres
ompared with the district hospital (95% CI 63.8—86.2). The
edian time between ART start and being lost to follow-up
tiretroviral therapy at the district hospital and health centres,
) Health centre n (%) P-value
1170
326 (27.9) <0.001
844 (72.1)
24 (2.0) <0.001
1146 (98)
0) 35.9 (29—42) —
2 (0.2) <0.001
1044 (89) <0.001
124 (11) <0.001
1066 (91.1) <0.001
104 (8.9)
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Table 2 Treatment outcomes for all patients started on antiretroviral treatment (ART) at hospital and health centres, Thyolo
District, Malawi
Hospital N (%) Rate/100pya Health centre N (%) Rate/100 pya Hazard ratio (95% CI) P-value
Started on ART 2904 — 1170 —
Retained in careb 2463 (84.9) 185 999 (85.4) 211 1.14 (1.06—1.23) <0.001
Alive and on ART 2385 (82.1) 179.3 994 (85.0) 210 1.17 (1.09—1.26) <0.001
Transferred out 79 (2.7) 5.94 5 (0.4) 1.06 0.17 (0.07—0.44) <0.001
Attritionc 439 (15.1) 33.3 171 (14.6) 36.1 1.07 (0.89—1.27) 0.5
Defaulted 227 (7.8) 17.0 18 (1.5) 3.8 0.22 (0.13—0.35) <0.001
Dead 202 (7.0) 15.2 150 (12.8) 31.7 2.02 (1.63—2.49) <0.001
Stopped 11 (0.4) 0.82 3 (0.3) 0.63 0.71 (0.19—2.57) 0.6a Rate/100 py: rate per 100 person-years of follow-up.
b Includes patients alive and on ART and formal transfer-outs.
c ART discontinuation due to default, death or stopping ART.
was 68 d [interquartile range (IQR) 41—126] at the hospital
and 126 d (IQR 106—179) at the health centres.
In contrast to rates of loss to follow-up, the incidence
of reported deaths was signiﬁcantly higher at the health
centres compared with the hospital [Table 2; adjusted HR
2.2, 95% CI 1.76—2.72, P < 0.001, attributable risk 52% (95%
CI 40.8—61.2)]. Of all cumulative deaths that occurred at
hospital (n = 202) and health centres (n = 150), 75% (151
at hospital and 112 at the health centre level) occurred
within the ﬁrst 3 months of starting ART (early mortal-
ity). Figure 2 shows the difference in probability of survival
among patients who started ART at hospital and health cen-
tres.
Table 3 shows the baseline characteristics of patients
who had ‘death’ as an outcome at health centres compared
with those alive and on ART or transferred out. Patients
with unexplained weight loss of over 10% constituted 35%
of all deaths and were at a signiﬁcantly higher risk of dying
[odds ratio (OR) 1.72, 95% CI 1.16—2.50, P = 0.005), as were
male patients (OR 2.1, 95% CI 1.4—3.0, P < 0.001). Patients
Figure 1 Probability of attrition (deaths, loss to follow-up and
stopped) among patients starting antiretroviral treatment (ART)
at hospital and health centres, Thyolo District, Malawi.
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iral treatment (ART) at hospital and health centres, Thyolo
istrict, Malawi.
ith severe bacterial infections and oral recurrent candidi-
sis constituted 11.3 and 23.3% of all deaths, respectively.
long with unexplained weight loss, these three conditions
ere associated with 69.6% of all deaths that occurred at
ealth centres.
. Discussion
n a rural district of Malawi, patients who had been started
n ART had higher retention and similar attrition rates at
he health centre level compared with the district hospital.
here has been much debate in Malawi about the appropri-
te level of care for offering ART, and in particular about
he success and safety of offering ART at health centres.
any African countries are now embarking on scaling up ART,
nd this issue is of wider importance in terms of policy and
ractice.10 In this light, the ﬁndings of this analysis raise a
umber of important observations that merit discussion.
First, retention rates both at hospital and health cen-
re level were close to 85%, and this seems acceptable in
598 M. Massaquoi et al.
Table 3 Characteristics of patients who were known to have died while on antiretroviral treatment at health centres, Thyolo
District, Malawi
Variable Died n (%) Alive/transferred out n (%) P-valuea
Total 150 (12.8) 999 (86.9) —
Sex
Male 63 (42) 259 (25.9) <0.001
Female 87 (58) 740 (74.1)
Age (years)
<35 86 (57.3) 542 (54.3) 0.47
≥35 64 (42.7) 457 (45.8)
WHO clinical stage
Stage I or II with CD4 <250 cells/l 0 2 (0.2)
Stage III 127 (84.7) 900 (90.1) 0.04
Stage IV 23 (15.3) 97 (9.7) 0.04
Main opportunistic infection at ART start
Oesophageal candidiasis 3 (2) 18 (1.8) 0.87
Kaposi’s sarcoma 7 (4.7) 19 (1.9) 0.06
Cryptococcal meningitis 1 (0.7) 2 (0.2) —
Oral recurrent candida 35 (23.3) 251 (25.1) 0.64
Unexplained chronic diarrhoea >1 month 14 (9.3) 108 (10.8) 0.58
Unexplained persistent fever >1 month 0 6 (0.6) —
Unexplained presumed weight loss >10% 52 (34.7) 237 (23.7) 0.003
Pneumocystis jiroveci pneumonia 3 (2) 84 (8.4) 0.005
Recurrent severe bacterial pneumonia 4 (2.7) 10 (1.0) 0.17
Active TB 13 (8.7) 90 (9.0) 0.89
Severe bacterial infection (pneumonia,
empyema, pyomyosities, meningitis,
suspected bacteraemia/septicaemia,
bone or joint infection)
17 (11.3) 136 (13.6) 0.44
Others (anaemia, skin conditions, herpes
simplex, anaemia, toxoplasmosis)
1 (3.3) 38 (3.8) 0.81
Duration on ART (months) [median (IQR)] 48 (24—92) 129 (51—263) —
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a 2 test.
he resource-limited setting.5 In the context of this anal-
sis a total of 3461 individuals was retained in care, and
his has associated beneﬁts not only for patients but also for
heir households and the wider community. We feel justiﬁed
n including transfer-outs as patients who are retained on
herapy. An operational research study in Northern Malawi
howed that over 90% of patients who transfer out have in
act ‘transferred in’ to another site and show good survival
utcomes.11
Second, districts such as Thyolo have been struggling to
et more HIV-positive TB patients on ART.12 The fact that
ore patients with active TB now access ART at health cen-
res than at hospital is likely to facilitate the linkage of ART
nd TB services at the primary level. This integration means
more TB-HIV accessible service and the possible perception
t patient level of ‘two diseases, one patient’.13
Third, the loss to follow-up rate was signiﬁcantly higher
t the hospital level (9.9%) than at the health centre level
1.5%). A loss to follow-up rate as low as 1.5% at health
entres is rarely reported in Africa.5 This important ﬁnding
ight be related to better geographical access and other
actors known to be important for ART uptake and continued
f
i
s
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tollow-up.2,4 This ﬁnding might also relate to better personal
nowledge by the provider of the patient (and vice versa).
Fourth, reported deaths constituted an important com-
onent of attrition and were signiﬁcantly higher at health
entre level. This may reﬂect weaker ascertainment (ascer-
ainment bias) of deaths among patients lost to follow-up
t the hospital level. A recent study from Malawi which
eported on the ‘true outcomes’ of patients lost to follow-
p showed that 65% of such patients were ascertained to
e dead or had stopped ART, 27% could not be traced
nd barely 8% were still on ART and had actually shifted
o another clinic.4 This ﬁnding coupled with the fact that
edian survival (without ART) in patients with AIDS in
frica is less than 1 year14 tend to support the argument
hat the rate of loss to follow-up needs to be taken into
onsideration when assessing death rates. This aside, the
eported mortality of 12.8% at the health centre is still
ar from desired, as high death rates challenge the cred-
bility of ART programmes in the eyes of patients, health
taff and the community. The great majority of deaths
75%) occurred early, within the ﬁrst 3 months of starting
reatment.
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There are several possible reasons for early mortality in
patients starting on ART, and these include: delayed pre-
sentation of patients, possibly inﬂuenced by a higher level
of stigma of HIV/AIDS in rural areas; delayed ART initi-
ation at the health facility and thus advanced HIV/AIDS
disease; delayed diagnosis; undiagnosed opportunistic infec-
tions; and life-threatening HIV-related complications such
as bacteraemia and TB.15 Unrecognized drug-related side
effects and drug interactions might also contribute to this
problem. Possible ways forward in addressing this high early
mortality have been discussed previously.16 In this study,
patients with unexplained weight loss of over 10%, recurrent
oral candidiasis and severe bacterial infections constituted
seven out of ten deaths at health centres. Is unexplained
weight loss a proxy for bacteraemia or undiagnosed TB, both
of which could present in an atypical or covert manner?17
A recent study from northern Malawi showed that 77% of
patients who developed TB after starting ART had unex-
plained weight loss and/or fever before starting ART, and
these observations concur with this hypothesis.18 In any
case, this is a group of patients in whom intensiﬁed case-
ﬁnding for TB and other opportunistic infections might be
worthwhile. Both recurrent oral candida and bacterial infec-
tions are conditions that can be diagnosed and treated at
health centre level. This raises the question about the qual-
ity of clinical assessment at this level and whether there are
stock interruptions of drugs known to be effective. Patients
with severe bacterial infections need a wider range of antibi-
otics than are currently available at the primary care level
as well as a higher level of clinical supervision to diagnose
and manage complications. Countries embarking on public
health scale-up of ART should therefore include a strong
training programme for non-physician clinicians on the early
recognition and prompt referral of opportunistic infections.
Fifth, there was a higher proportion of deaths in males
compared with females, and this observation may be
due to men seeking medical care at a more advanced
stage of immunodeﬁciency and showing poorer compli-
ance with therapy.19 This issue also needs to be more
actively addressed in the scaling-up process through tar-
geted information and education sessions as well as targeted
counselling.
Finally, Thyolo District beneﬁts from assistance from the
Department of International Development (DFID), Family
Health International (FHI), Norwegian Agency for Develop-
ment Cooperation (NORAD) and other agencies, as well as
additional technical and ﬁnancial assistance from Médecins
Sans Frontières. In many settings in sub-Saharan Africa such
resources, particularly at ﬁrst contact level, are extremely
scarce and do not allow allocation of a mobile team, a
medical assistant, a nurse, a clerk and a receptionist exclu-
sively to ART delivery, for example. Our ﬁndings might thus
not apply to rural settings, which are relatively less well
resourced than Thyolo. Malawi, like other countries in sub-
Saharan Africa, is facing a serious shortage of health staff,
particularly doctors and specialists,20,21 and decentralisation
of ART delivery to health centres will require alternative
strategies, including task shifting,21—23 as well as increased
resources for stafﬁng, training, supervision and support for
referrals.
The strengths of this study were: that a large number
of patients were included in the study; that outcomes were
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eliably ascertained using master cards and registers, which
re robust and regularly checked by supervision teams; and
s the data come from a programme setting the ﬁndings
robably reﬂect the operational reality on the ground. The
imitations of the study were: that there were no data on
ariables such as HIV- or drug-related morbidity; that the
auses of death or reasons for default were not ascertained
ut merit speciﬁc investigation; that CD4 count measure-
ents were not performed at health centre level, and we
ere thus unable to compare the degree of immunode-
ciency between hospital-based and health-centre-based
atients; and ﬁnally, there were fewer children initiated
n ART at health centres as children were by preference
eferred to the district hospital. There is also the consider-
tion that retention and attrition patterns might change as
he cohort matures.
In conclusion, as Malawi continues to extend the coverage
and equity) of ART, including in rural areas, attention is
eeded to reduce losses to follow-up at hospital level and
educe mortality at primary care level.
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